A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs INCB 59872 (Primary) ; Azacitidine; Nivolumab; Tretinoin
  • Indications Acute myeloid leukaemia; Cancer; Small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 08 Dec 2017 Planned number of patients changed from 180 to 215.
    • 01 Nov 2017 Planned number of patients changed from 108 to 180.
    • 01 Nov 2017 Planned End Date changed from 1 Apr 2018 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top